PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2012; 7(7): e41501.
Published online Jul 25, 2012. doi:  10.1371/journal.pone.0041501
PMCID: PMC3405087
Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine
William C. Weldon,1 Vladimir G. Zarnitsyn,2 E. Stein Esser,1 Misha T. Taherbhai,1 Dimitrios G. Koutsonanos,1 Elena V. Vassilieva,1 Ioanna Skountzou,1 Mark R. Prausnitz,2 and Richard W. Compans1*
1Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America
2School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America
Mauricio Martins Rodrigues, Editor
Federal University of São Paulo, Brazil
* E-mail: rcompan/at/emory.edu
Conceived and designed the experiments: WCW RWC VGZ MRP. Performed the experiments: WCW VGZ ESE MTT. Analyzed the data: WCW. Contributed reagents/materials/analysis tools: DGK EVV IS. Wrote the paper: WCW RWC MRP.
Received April 17, 2012; Accepted June 21, 2012.
Recent studies have demonstrated the effectiveness of vaccine delivery to the skin by vaccine-coated microneedles; however there is little information on the effects of adjuvants using this approach for vaccination. Here we investigate the use of TLR ligands as adjuvants with skin-based delivery of influenza subunit vaccine. BALB/c mice received 1 µg of monovalent H1N1 subunit vaccine alone or with 1 µg of imiquimod or poly(I:C) individually or in combination via coated microneedle patches inserted into the skin. Poly(I:C) adjuvanted subunit influenza vaccine induced similar antigen-specific immune responses compared to vaccine alone when delivered to the skin by microneedles. However, imiquimod-adjuvanted vaccine elicited higher levels of serum IgG2a antibodies and increased hemagglutination inhibition titers compared to vaccine alone, suggesting enhanced induction of functional antibodies. In addition, imiquimod-adjuvanted vaccine induced a robust IFN-γ cellular response. These responses correlated with improved protection compared to influenza subunit vaccine alone, as well as reduced viral replication and production of pro-inflammatory cytokines in the lungs. The finding that microneedle delivery of imiquimod with influenza subunit vaccine induces improved immune responses compared to vaccine alone supports the use of TLR7 ligands as adjuvants for skin-based influenza vaccines.
Seasonal influenza vaccination is currently recommended in the United States for all population groups including high risk populations such as elderly or immunocompromised individuals [1]. Due to antigenic variation in viral glycoproteins and limited duration of immunity, annual vaccination is required to maintain protective immunity. To reduce the burden of re-vaccination during pandemics or seasonal drift of vaccine strains, vaccine efficacy can be enhanced by using alternative routes of immunization or by the addition of adjuvants to vaccine formulations.
The use of adjuvants with licensed influenza vaccines has focused on oil-in-water emulsions such as MF59™. Vesikari et al. demonstrated the enhanced immunogenicity of MF59 adjuvanted trivalent influenza vaccine in young children [2]. In addition, use of MF59 with avian influenza viruses (H5N1) also showed enhancement of the immune response in adults including the elderly [3]. In the United States, the only approved adjuvants for use in vaccines are aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (alum) and AS04, which contains both alum and monophosphoryl lipid A [4], [5]. In Europe, the adjuvant MF59 (oil-in-water emulsion) has been approved for use in vaccines since the 1990’s [5].
Increasingly, much work has begun to focus on adjuvants which signal through pattern recognition receptors (PRRs) including Toll-like receptors (TLRs). TLR ligands such as lipopolysaccharide, bacterial flagellin, poly(I:C) and imiquimod provide stimulation to the innate immune system resulting in the upregulation of CD80/86, production of IL-12, and increased MHC II expression [6][9]. Upregulation of costimulatory molecules and production of cytokines by matured dendritic cells play an important role in efficient stimulation of antigen-specific naïve lymphocytes and activation of the adaptive immune response.
Skin-based vaccinations have been shown to be an effective immunization route for a variety of pathogens. Previously, intradermal immunization using seasonal influenza vaccine has demonstrated 5-fold dose-sparing effects [10]. However, this route of skin vaccination relied on the use of the Mantoux injection method, which is known to be technically difficult [11][13]. Recent studies have introduced more reliable devices for intradermal injection of influenza vaccine [14]. Our labs have demonstrated that the use of microneedles patches coated with influenza vaccine antigens results in the induction of protective immune responses in animal models. Furthermore, this vaccination route induces immune responses that are equal to if not better than traditional needle based routes [15][17].
The types of adjuvants delivered to the skin previously include poly[di(carboxylatophenoxy)phosphazene] (PCPP) [18], CpG oligonucleotides (TLR9 ligands) [19], trimethyl chitosan [20], alum [21], QS-21 [22] and bacterial endotoxins, such as cholera toxin or heat labile toxin [23], [24]. However, little work has been reported to evaluate the effectiveness of TLR3 or 7 ligands when delivered into the skin via microneedle patches.
In the current study, we have compared the skin delivery of adjuvanted influenza subunit vaccine with coated microneedles using imiquimod or poly(I:C), both mimics of viral RNA intermediates. We have compared the immune responses, HAI and microneutralization titers as well as frequencies of IFN-γ+ effector helper T cells. The effects of the adjuvanted vaccine on protection against lethal challenge with the homologous virus were also compared to those of vaccine alone. This report highlights the first work describing the delivery of TLR3 and TLR7 ligand adjuvants by coated microneedles to the skin with an influenza subunit vaccine.
Skin Delivery of Adjuvanted Influenza Subunit Vaccine Increases Humoral Immune Response
To test the effect of co-delivery of poly(I:C), imiquimod, or a combination of both adjuvants with a licensed influenza subunit vaccine, female BALB/c mice (6 weeks old) were vaccinated by coated microneedles with 1 µg H1N1 HA and 1 µg of each adjuvant. On day 14, 100% (6/6) of animals seroconverted, and by day 28 IgG titers were equivalent in all vaccinated groups. The serum antibody levels indicate that microneedle delivery of influenza subunit vaccine induces antibodies against the homologous virus. Furthermore, co-delivery of imiquimod or poly(I:C) alone or in combination did not significantly enhance the serum IgG response (Figure 1A).
Figure 1
Figure 1
Microneedle immunization with imiquimod-adjuvanted influenza subunit vaccine enhances IgG2a isotype responses.
Adjuvants are capable of influencing the adaptive immune response and inducing a type 1 helper T cell phenotype resulting in isotype switching to IgG2a [25]. Influenza specific IgG1 and IgG2a were measured in sera collected from mice on day 28 after microneedle vaccination with H1N1 vaccine alone or with imiquimod or poly(I:C) alone or in combination. The data indicate a robust IgG1 response in all vaccinated groups. However, addition of imiquimod resulted in a significant increase in virus specific IgG2a (p = 0.0002). The IgG2a subtype is associated with the type 1 helper T cell phenotype and enhanced virus neutralization [26]. Thus, although microneedle delivery of H1N1 subunit vaccine with imiquimod did not induce a quantitatively different serum IgG response, it did induce a qualitatively different response (Figure 1B).
Effects of Poly(I:C) and Imiquimod on HAI Titers
Because we detected a qualitative difference in the immunoglobulin isotypes following vaccination with and without imiquimod, we measured the titer of functional antibodies by using a hemagglutination inhibition (HAI) assay. In general, an HAI titer of ≥40 correlates with protection in humans [27]. Serum collected on day 28 from mice vaccinated with H1N1 alone or with imiquimod or poly(I:C) alone or in combination were tested for HAI titers. All mice vaccinated with H1N1 subunit vaccine and imiquimod (9/9) had HAI titers greater than or equal to 40, whereas approximately 33% of mice receiving H1N1 vaccine alone had HAI titers greater than or equal to 40. In addition, mice vaccinated with H1N1 subunit vaccine and imiquimod had approximately 2-fold higher HAI titers compared to mice vaccinated with H1N1 alone vaccine (p<0.001). Interestingly, the combination of poly(I:C) and imiquimod did not further boost the HAI titers compared to the imiquimod alone (p = .22) (Figure 2). Therefore, co-delivery of imiquimod with influenza subunit vaccine induces higher titers of functional HAI antibodies compared to vaccine alone.
Figure 2
Figure 2
Imiquimod co-delivered with influenza subunit vaccine on coated microneedles induces higher HAI titers compared to vaccine alone.
Microneedle Vaccination with Influenza Subunit Vaccine and Imiquimod Induces Higher Frequency of IFN-γ+CD4+ T Cells
T cell-derived cytokines can influence the B cell and CD8+ T cell response. [28], [29]. Therefore to determine the helper T cell phenotype, on day 14 post-vaccination we isolated the inguinal lymph nodes and purified T cells from the spleens of vaccinated mice (n = 3) and restimulated the cells with vaccine being presented by accessory cells. The cytokines IFN-γ and IL-4 are known to be produced by helper T cell type 1 and helper T cell type 2, respectively. Stimulated cells were assayed for the production of these cytokines by ELISA and intracellular cytokine staining. Mice vaccinated with subunit vaccine and imiquimod had approximately 2-fold higher IFN-γ secretion levels in stimulated splenic T cells (p = 0.01) and approximately 2.8-fold higher levels in the draining lymph node (p = 0.03) (Figure 3 A,B). In addition, we observed approximately 1.6-fold higher IL-4 secretion from stimulated splenic T cells from mice immunized with vaccine and poly(I:C) compared to mice immunized with vaccine alone (p = 0.101), while vaccination with imiquimod increased IL-4 expression approximately 2.3-fold over vaccine alone in the draining lymph node (p = 0.23). Intracellular staining of the stimulated draining lymph node cells indicated that microneedle vaccination with influenza subunit vaccine and imiquimod resulted in a 2.1-fold higher frequency of CD4+CD62L-IFNγ+ T cells (p = 0.02) and a 1.7-fold higher frequency of CD4+CD62L-IL4+ T cells compared to vaccine alone (p = 0.05)(Figure 3 C,D). These data indicate that the addition of adjuvants with the microneedle vaccine increases the frequency of type 1 helper T cells. In addition, these results support the IgG isotype data we obtained, suggesting that this increased frequency of IFN-γ+ helper T cells plays a role in inducing the IgG2a isotype after immunization with the imiquimod adjuvanted subunit vaccine.
Figure 3
Figure 3
Microneedle immunization with imiquimod and influenza subunit vaccine elicits a robust IFN-γ cellular immune response.
Immunization with Influenza Subunit Vaccine and Imiquimod-coated Microneedles Induces Improved Protective Immune Responses
To determine the efficacy of the adjuvanted influenza subunit microneedle vaccines, we challenged vaccinated mice intranasally with 5×LD50 or 20×LD50 of the mouse adapted A/California/07/2009, 28 days after immunization. Body weights and survival were monitored for 14 days post-challenge. Following lethal challenge with 5×LD50, mice immunized with subunit vaccine and imiquimod or imiquimod and poly(I:C) in combination survived infection resulting in a maximal average body weight loss of approximately 2% and 4%, respectively, by day 5. Mice immunized with subunit vaccine alone or with poly(I:C) lost approximately 10% and 8%, respectively, while all naïve mice succumbed to infection. This difference in retention of body weight following lethal challenge was statistically significant when imiquimod-adjuvanted vaccine is compared to subunit vaccine alone (p = 0.04,p = 0.01)(Figure 4A).
Figure 4
Figure 4
Microneedle immunization with imiquimod and influenza subunit vaccine confers enhanced protection against lethal challenge with mouse adapted A/California/07/2009 virus.
Following lethal challenge with 20×LD50, mice vaccinated with subunit vaccine alone lost approximately16% of their initial body weight by day 5 and showed a survival rate of 66% (4/6). Notably, all groups of mice that were immunized with adjuvanted influenza vaccine survived the higher lethal challenge, with imiquimod providing the lowest body weight loss (10%)(Figure 4 B,C). Thus addition of imiquimod to microneedle-delivered subunit influenza vaccines improves the protective immune response to a high lethal challenge dose.
Imiquimod Enhances Viral Lung Clearance and Reduces Production of Pro-inflammatory Cytokines
To determine the ability of mice to clear viral replication in the lungs, we examined the viral lung titers 4 days post-challenge with 20×LD50 of the homologous virus. Mice vaccinated with the subunit vaccine and imiquimod exhibited enhanced clearance of virus with an approximately 2.5-log greater reduction in virus titers compared to subunit vaccine alone (p = 0.01). In contrast, addition of poly(I:C) to the vaccine formulation did not significantly improve clearance of virus from the lungs compared to the subunit vaccine alone (p = 0.79)(Figure 5A).
Figure 5
Figure 5
Imiquimod induces improved clearance of replicating virus from the lung and reduced production of pro-inflammatory cytokines in response to challenge.
The production of pro-inflammatory cytokines in the lungs in response to influenza infection has been attributed to cellular infiltration and tissue damage. In addition, this cytokine storm is associated with morbidity in humans [30], [31]. To determine the expression of inflammatory mediators we determined the expression levels of TNFα and IL-6 in the lungs after 20×LD50 challenge. We observed a significant reduction in levels of both cytokines in mice immunized with subunit vaccine and imiquimod versus vaccine alone using coated microneedles (p = 0.02, p = 0.04) (Figure 5B,C). This suggests that the addition of imiquimod to the influenza subunit microneedle vaccine allows for rapid clearance of replicating virus in the lungs and reduces the level of the cytokine storm, resulting in reduced immunopathology.
The use of adjuvants with influenza vaccines has been shown to induce improved immune responses [32][35]. However, these approaches have relied on the use of traditional needle-and-syringe delivery methods. Skin-based vaccination strategies using microneedle delivery systems are an attractive alternative and take advantage of the large population of innate immune cells including dermal dendritic cells and Langerhans cells. In addition, this vaccine delivery method has other advantages including a painless vaccination [36].
In the present study, we tested the hypothesis that microneedle delivery of the TLR7 and TLR3 ligands imiquimod and poly(I:C), respectively, to the skin with a licensed monovalent influenza H1N1 subunit vaccine will enhance the immune response in mice, compared to microneedle immunization with vaccine alone. We demonstrated that although the total IgG response was not significantly enhanced following microneedle immunization using influenza vaccine and adjuvant coated microneedles compared to vaccine alone, there were significant increases in the induction of IgG2a and functional antibodies blocking receptor binding using adjuvanted subunit vaccine and microneedle delivery.
CD4+ T cells play an important role in inducing class switching in B cells. In addition to induction of class switching to IgG2a, IFN-γ has also been shown to induce an anti-viral state, and upregulate MHC class I and II [37], [38]. Therefore we measured the expression of a Th1 (IFN-γ) and a Th2 (IL-4) cytokine in mice receiving adjuvanted microneedle vaccines. We observed that vaccination with influenza subunit vaccine and imiquimod resulted in a higher frequency of IFN-γ+ effector CD4+ T cells compared to mice immunized with subunit vaccine alone. This correlated with the induction of IgG2a in the sera of mice vaccinated with subunit vaccine and imiquimod.
Further investigation into the protective immune responses indicated that adjuvanted microneedle subunit vaccine improved resistance to lethal challenge compared to vaccine only. Notably, microneedle vaccination with subunit vaccine and imiquimod resulted in improved clearance of virus from lungs. Previous studies using the 1918 H1N1 virus and highly pathogenic avian H5N1 virus suggest that a strong induction of pro-inflammatory cytokines in the lungs results in immunopathology [30], [39], [40]. We observed a reduction in pro-inflammatory cytokines in the lungs of mice that were immunized with subunit vaccine and imiquimod, which correlated with reduced body weight loss. These data suggest that microneedle vaccination with influenza subunit vaccine and imiquimod is capable of reducing immunopathology associated with infection.
It is interesting to note that the tissue expression pattern of TLRs varies greatly in mice. In murine skin, previous studies have demonstrated that isolated Langerhans cells express TLRs 2,4, and 9 mRNA [41]. Fujita et al have demonstrated that murine Langerhans cells expressed TLR3 mRNA; however they exhibited low responsiveness to poly(I:C) [42]. In our studies, delivering the TLR3 ligand, poly(I:C) using the coated microneedles did not enhance the immune response, in agreement with these findings. In addition, a recent study by Hasan et al [43] suggests that responses to topical poly(I:C) can be inhibited by anti-microbial peptides. These antimicrobial peptides are upregulated in response to disruption of the skin barrier, suggesting that the lack of a response to poly(I:C) could be due in part to this response [44].
Conversely, TLR7 has not been shown to be expressed in the skin at steady state conditions [41]. However, Suzuki et al have demonstrated that as a topically applied cream imiquimod induces migration of Langerhans cells from the skin and to the draining lymph nodes [45]. Thus, the delivery of both vaccine antigen and imiquimod by coated microneedles allows for direct uptake of vaccine by Langerhans cells and TLR7-dependent enhancement of migration to draining lymph nodes.
Recent work by our lab investigated microneedle delivery of the A/Brisbane/59/2007 H1N1 subunit vaccine and compared immune responses to intramuscular vaccination [46]. The results indicated that microneedle vaccination with 3 µg of A/Brisbane/59/2007 induced higher serum IgG2a levels compared to intramuscular vaccination at 4 weeks post-immunization. Furthermore, at 12 weeks post-immunization a higher frequency of IFN-γ secreting splenocytes was observed in mice vaccinated with coated microneedles compared to mice vaccinated intramuscularly suggesting a Th1 cytokine environment. Our present results with 1 µg of A/California/07/2009 antigen complement these results and suggest increased dose-sparing with similar body weight loss at 5×LD50 and improved survival after 20×LD50 challenge. The addition of MF59 has been shown to enhance immune responses to the California/07/2009 in adults receiving a single intramuscular vaccination with 3.75 µg of subunit vaccine [47]. In the mouse model, MF59 adjuvanted A/California/07/2009 (0.5 or 1 µg) subunit vaccine was also more immunogenic compared to vaccine alone. [48]. Although MF59 has been shown to be a very effective adjuvant, it is probably unsuitable to be coated onto solid microneedles due to its lipid content.
These results demonstrate the efficacy of vaccination using microneedles coated with influenza subunit vaccine and imiquimod. The imiquimod-adjuvanted vaccine induced greater functional antibody titers and enhanced cellular responses, inducing improved protective immune responses in mice. It is noteworthy that imiquimod is currently FDA-approved for human use when applied to the skin. In addition to TLR agonist adjuvants, other mediators of innate immunity including cytokines need to be investigated further. Taken together our results indicate that the use of adjuvants with coated-microneedle vaccines is a feasible approach for at enhancing the anti-viral immune response.
Influenza Vaccine and Adjuvants
H1N1 monovalent subunit influenza vaccine (A/California/07/2009) was kindly provided by Novartis Vaccine and Diagnostics (Boston, MA). Polyinosinic-polycytidylic acid (poly(I:C)) and imiquimod were purchased from Invivogen (San Diego, CA).
Microneedle Fabrication and Coating
Microneedles were fabricated from stainless steel sheets (SS 304, 50 µm thick, Trinity Brand Industries – Countryside, IL) by lithography and wet etching. Individual microneedles had a length of 750 µm and width of 200 µm, and were assembled in rows of five microneedles each.
Microneedles were coated using a solution composed of 1% (w/v) carboxymethylcellulose sodium salt (low viscosity, USP grade, Carbo-Mer - San Diego, CA), 0.5% (w/v) Lutrol F-68 NF (BASF - Mt. Olive, NJ), soluble HA protein at 5 mg/ml and, unless otherwise noted, 15% (w/v) trehalose (Sigma – St. Lois, MO) [49]. In order to obtain a high vaccine concentration in the coating solution, we used evaporation for 5–10 minutes at room temperature (23°C) at the final step of preparation (Vacufuge - Eppendorf, NY). The coating step was performed by a dip coating process [50]. The apparatus had a chamber with coating solution and microneedle holder which was attached to a linear stage that allowed the microneedle array to move in two dimensions with 0.4 µm accuracy. The coating was automated and was monitored by a video camera attached to a computer.
To measure the amount of vaccine coated per row of microneedles, three rows out of each batch of coated microneedles were submerged into 200 µL of PBS buffer for 5 minutes to dissolve the antigen. The concentration of protein in the solution was measured by the BCA protein assay (Pierce - Rockford, IL) and was found to be consistent to ±10% within each batch.
Vaccinations
Female BALB/c mice (6–8 weeks) were anesthetized with a xylazine/ketamine cocktail intraperitoneally and hair on the lower back removed with a depilatory cream (Nair, Church & Dwight Co. – Colonial Heights, VA) two days prior to microneedle vaccination. Mice were anesthetized again and microneedle arrays coated with 1 µg of subunit influenza vaccine alone or with 1 µg imiquimod, 1 µg poly(I:C) alone or the combination of both adjuvants were inserted into the skin and left in place for 5 minutes to allow the vaccine coating to dissolve. All animal studies were approved by the Emory University Institutional Animal Care and Use Committee (IACUC).
Virus and Challenge
To determine vaccine efficacy, vaccinated mice were lightly anesthetized with isofluorane (4%) until recumbent and challenged by slow intranasal inoculation of 30 µL containing 5×LD50 or 20×LD50 of live mouse adapted A/California/07/2009 (H1N1) virus. Body weight loss and survival rates were monitored daily for 14 days post-challenge. Weight loss ≥25% was used as the end-point at which mice were euthanized according to IACUC guidelines.
Viral Lung Titers and Inflammatory Cytokine ELISA
Mouse lungs were collected on day 4 post-challenge as previously described [15]. Madin-Darby canine kidney cells were maintained at a low passage number in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Hyclone, ThermoFisher - Rockford, IL). Plaque assays were performed on lung homogenates from challenged mice as previously described [51]. Lung supernatants in DMEM prepared from immunized mice on day 4 post-challenge were assayed for IL-6 and TNF-α according to the manufacturer’s instructions (eBioscience – San Diego, CA).
ELISA
IgG ELISA was performed on serum and lung homogenates as previously described [15], [17]. All horseradish-peroxidase (HRP) conjugated secondary antibodies to mouse IgG, IgG1, and IgG2a were purchased from Southern Biotechnology Associates (Birmingham, AL). Briefly, 96-well immunoplates (Nunc, Co - Rochester, NY) were coated overnight at 4°C with 4 µg of inactivated A/California/07/2009 virus per well. Plates were washed with PBS-Tween (0.05%) and blocked with PBS-Tween supplemented with 3% BSA. Sera were diluted 1[ratio]100 and incubated for 1.5 hours at 37°C. Plates were washed 3 times with PBS-Tween (0.05%) and incubated for 1.5 hours at 37°C in a 1[ratio]1000 dilution of goat, anti-mouse HRP-conjugated secondary antibody (Southern Biotechnology – Birmingham, AL). Plates were then washed 3 times with PBS-Tween (0.05%) and OPD substrate (Invitrogen – Carlsbad, CA), added to each well and color allowed to develop for 10 minutes. Color development was stopped using 1 M phosphoric acid. Absorbances were read at 450 nm on a Biorad Model 680 microplate reader. IgG concentrations were determined by linear regression of a standard curve of known concentrations. Absorbances for IgG1 and IgG2a were corrected for background (no antigen).
Hemagglutination Inhibition Assay (HAI)
HAI tests were performed on vaccinated animal sera based on the World Health Organization protocol [52]. Briefly, sera were treated with receptor destroying enzyme (Denka Seiken, Tokyo, Japan) for 16 hours at 37°C then heat inactivated for 30 minutes at 56°C. Treated sera were diluted to a final concentration of 1[ratio]10 in PBS and incubated with packed chicken red blood cells (RBC) for 1 hour at 4°C to remove cryoglobulins. Treated sera were serially diluted and incubated with 4 HA units of A/California/07/2009 virus for 30 minutes at room temperature. An equal volume of 0.5% chicken RBC was added to each well and incubated for 30 minutes at room temperature. The HAI titer was read as the reciprocal of the highest dilution of serum that inhibited hemagglutination. Values were expressed as the geometric mean with a 95% confidence interval.
Cellular Immune Responses
Single cell suspensions were prepared from spleens and inguinal lymph nodes of mice 14 days post vaccination or naïve mice, by mincing the tissue through a 70 µm cell strainer (BD Falcon - San Jose, CA). Splenocytes preparations were incubated in red blood cell lysing buffer (Sigma) to remove RBCs. T cells were purified by negative selection using BD iMag magnetic cell separation (BD Biosciences – San Jose, CA). Naïve splenocytes were treated with Mitomycin C for 30 minutes and used as accessory cells (2.5×105 cells/well) after incubation with 5 µg of vaccine in complete RPMI overnight at 37°C in a 5% CO2 incubator in a 96-well round bottom microtiter plate (Nunc, Co – Rochester, NY). Purified T cells or lymph node cells were added to accessory cells at a ratio of 4[ratio]1 and 3[ratio]1 (responder:accessory), respectively, in complete RPMI medium supplemented with 30 U of recombinant human IL-2 (BD Biosciences). In vitro antigen-specific stimulation was measured after incubation for 5 days by intracellular cytokine staining. Supernatants of stimulated cells were collected and clarified by centrifugation for IFN-γ and IL-4 ELISA, performed according to the manufacturer’s instructions (eBioscience – San Diego, CA).
Antibodies and Flow Cytometry
Cells were washed with PBS, 1% BSA buffer and surface stained with fluorochrome-conjugated antibodies to CD4, CD62L, and CD3, followed by intracellular staining of IFN-γ and IL-4. Antibodies were purchased from eBiosciences (San Diego, CA) and BD Biosciences. For intracellular cytokine staining, cells were fixed and permeabilized using the BD Cytofix/Cytoperm manufacturer’s protocol and reagents (BD Bioscience). The data were acquired on a BD LSR-II and analyzed with FloJo Software (v7.6.1, Tree Star – Ashland, OR).
Statistics
Statistical analysis was done using the one-way ANOVA analysis with GraphPad Prism5 software (La Jolla, CA). All data followed normal Gaussian distributions unless otherwise noted. Viral lung titers and HAI titers were transformed to log10 and log2 titers, respectively, for statistical analysis using one-way ANOVA. A P value less than 0.05 was considered as a significant difference.
Acknowledgments
We thank Erin-Joi Collins for her valuable assistance in the preparation of this manuscript. We also thank Kiran Gill at the Emory Vaccine Center Flow Cytometry Core for technical support.
Footnotes
Competing Interests: The authors have the following interests: M.R.P. is an inventor of patents that have been licensed to companies developing microneedle-based products, i.e. Coated Microstructures and Methods of Manufacture Thereof U.S. patent application 20080213461 which has been exclusively licensed to Apogee Technology. M.R.P. is a founder/shareholder in Clearside Biomedical and Microneedle Systems. This company does not have a direct financial interest in the research in this paper, but could indirectly benefit. For this reason, this study could affect Dr. Prausnitz’s personal financial status. This potential conflict of interest has been disclosed and is overseen by Georgia Tech and Emory University. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Funding: The work was supported in part by U.S. National Institutes of Health grants AI074579, EB006369 and EB012495. DK was supported by a fellowship from National Institutes of Health/National Institute of Allergy and Infectious Diseases HHSN266200700006C Center of Excellence for Influenza Research and Surveillance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
1. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1128–1132. [PubMed]
2. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563–571. [PubMed]
3. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, et al. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol. 2010;17:1817–1819. [PMC free article] [PubMed]
4. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488–496. [PubMed]
5. El Sahly H. MF59™; as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010;9:1135–1141. [PubMed]
6. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, et al. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol. 2001;166:249–255. [PubMed]
7. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol. 2011;186:2422–2429. [PMC free article] [PubMed]
8. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol. 2001;166:5688–5694. [PubMed]
9. Larange A, Antonios D, Pallardy M, Kerdine-Romer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol. 2009;85:673–683. [PubMed]
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295–2301. [PubMed]
11. Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol. 2012;351:77–112. [PMC free article] [PubMed]
12. Flynn PM, Shenep JL, Mao L, Crawford R, Williams BF, et al. Influence of needle gauge in Mantoux skin testing. Chest. 1994;106:1463–1465. [PubMed]
13. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26:3197–3208. [PubMed]
14. Atmar RL, Patel SM, Keitel WA. Intanza((R)): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010;9:1399–1409. [PubMed]
15. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One. 2009;4:e4773. [PMC free article] [PubMed]
16. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, et al. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine. 2009;27:6932–6938. [PMC free article] [PubMed]
17. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol. 2011;18:647–654. [PMC free article] [PubMed]
18. Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A. 2009;106:18936–18941. [PubMed]
19. Slutter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release. 2011;154:123–130. [PubMed]
20. Bal SM, Slutter B, Verheul R, Bouwstra JA, Jiskoot W. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci. 2012;45:475–481. [PubMed]
21. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One. 2010;5:e13460. [PMC free article] [PubMed]
22. Chen D, Endres R, Maa YF, Kensil CR, Whitaker-Dowling P, et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine. 2003;21:2830–2836. [PubMed]
23. Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett. 2005;97:181–188. [PubMed]
24. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol. 1998;161:3211–3214. [PubMed]
25. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–680. [PubMed]
26. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006;13:981–990. [PMC free article] [PubMed]
27. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767–777. [PMC free article] [PubMed]
28. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol. 2009;10:385–393. [PMC free article] [PubMed]
29. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852–856. [PubMed]
30. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203–1207. [PubMed]
31. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146:980–991. [PMC free article] [PubMed]
32. Schneider-Ohrum K, Giles BM, Weirback HK, Williams BL, DeAlmeida DR, et al. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine. 2011;29:9081–9092. [PubMed]
33. Barrett PN, Ehrlich HJ. Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1). Lancet Infect Dis 11: 496–497; author reply 497–498. 2011. [PubMed]
34. Launay O, Desaint C, Durier C, Loulergue P, Duval X, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis. 2011;204:124–134. [PMC free article] [PubMed]
35. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365:1406–1416. [PubMed]
36. Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008;24:585–594. [PMC free article] [PubMed]
37. Coffman RL, Savelkoul HF, Lebman DA. Cytokine regulation of immunoglobulin isotype switching and expression. Semin Immunol. 1989;1:55–63. [PubMed]
38. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189. [PubMed]
39. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007;445:319–323. [PubMed]
40. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol. 2007;85:85–92. [PubMed]
41. Mitsui H, Watanabe T, Saeki H, Mori K, Fujita H, et al. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol. 2004;122:95–102. [PubMed]
42. Fujita H, Asahina A, Mitsui H, Tamaki K. Langerhans cells exhibit low responsiveness to double-stranded RNA. Biochem Biophys Res Commun. 2004;319:832–839. [PubMed]
43. Hasan M, Ruksznis C, Wang Y, Leifer CA. Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses. J Immunol. 2011;187:5653–5659. [PMC free article] [PubMed]
44. Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol. 2001;117:91–97. [PubMed]
45. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135–141. [PubMed]
46. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep. 2012;2:357. [PMC free article] [PubMed]
47. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009;361:2424–2435. [PubMed]
48. Dormitzer PR, Rappuoli R, Casini D, O’Hagan D, Runham C, et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr. 2009;1:RRN1025. [PMC free article] [PubMed]
49. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010;142:187–195. [PMC free article] [PubMed]
50. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007;117:227–237. [PMC free article] [PubMed]
51. Sha Z, Compans RW. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol. 2000;74:4999–5005. [PMC free article] [PubMed]
52. World Health Organization. WHO manual on animal influenza diagnosis and surveillance. 2002. http://www.wpro.who.int/NR/rdonlyres/EFD2B9A7-2265-4AD0-BC98-97937B4FA83C/0/manualonanimalaidiagnosisandsurveillance.pdf.
Articles from PLoS ONE are provided here courtesy of
Public Library of Science